Javascript must be enabled to continue!
Post-procedural high platelet reactivity with prasugrel loading predicts in-hospital adverse events in ACS patients
View through CrossRef
Abstract
Background/Introduction
High platelet reactivity (HPR) is associated with adverse cardiovascular events, primarily intrastent thrombosis, after a percutaneous coronary intervention (PCI). However, the relationship between hyperacute postprocedural HPR with prasugrel loading and clinical outcomes in acute coronary syndrome (ACS) remains unclear. Moreover, factors contributing to HPR in ACS with prasugrel loading are also unknown.
Purpose
To assess the effects of post-procedural HPR with prasugrel loading on clinical outcomes in ACS during hospitalization, and to define the appropriate cut-off values and identify factors contributing to HPR.
Methods
A single-center, retrospective observational study that enrolled 154 patients who underwent emergent PCI for ACS with prasugrel loading was performed. The P2Y12 reaction unit (PRU) value was measured immediately after PCI using the VerifyNowR system. The primary end-point was major adverse cardiac events (MACE, defined as the composite of death, myocardial infarction, stroke, heart failure, ventricular arrhythmia needing defibrillation).
Results
The mean patient age (standard deviation) was 70.7 (±12.5) years, 76.6% were men, and the average time from the prasugrel intake to PRU calculation was 103.2 (±48.5) min. During the mean hospital stay of 15.6 (±8.5) days, 24 in-hospital MACE (15.5%) and 8 deaths (5.2%) occurred. Thrombosis events, including myocardial infarction recurrence, did not occur (only one case of spontaneous coronary artery dissection was considered as myocardial infarction recurrence). PRU was significantly higher in the MACE group than that in Non-MACE group (287±55 and 232±64, respectively, p<0.001). The ROC curve analysis of PRU for discriminating the significant in-hospital MACE showed the cut-off value of 293 (sensitivity: 62.5%, specificity: 83.1% [AUC=0.756, p<0.0001]). A total of 37 patients (24%) were thus categorized as HPR (PRU>293) immediately after the emergent PCI. Kaplan-Meier curve showing MACE events occurred in the HPR group than that in the non-HPR group (40.5% vs 7.6%, p<0.001). Multiple cox analysis demonstrated that HPR was independent predictors of MACE in patients with ACS who underwent PCI (OR 11.01, 95% CI 2.39–20.2, p<0.0001). Multiple logistic regression model showed old age, female sex, low systolic blood pressure, short prasugrel intake to measure time, and large acute gain were independent predictors of HPR.
Conclusion
PRU was significantly higher in the MACE group, with an appropriate cut-off value of HPR of 293 in this study. HPR was an independent predictor of MACE during hospitalization; however, thrombosis events were not significant. HPR predictors were old age, female sex, low systolic blood pressure, short prasugrel intake to measure time, and large acute gain. This study shows the post-procedural HPR with prasugrel loading in patients with ACS can be a useful predictive marker of adverse events during hospitalization.
Funding Acknowledgement
Type of funding source: None
Oxford University Press (OUP)
Title: Post-procedural high platelet reactivity with prasugrel loading predicts in-hospital adverse events in ACS patients
Description:
Abstract
Background/Introduction
High platelet reactivity (HPR) is associated with adverse cardiovascular events, primarily intrastent thrombosis, after a percutaneous coronary intervention (PCI).
However, the relationship between hyperacute postprocedural HPR with prasugrel loading and clinical outcomes in acute coronary syndrome (ACS) remains unclear.
Moreover, factors contributing to HPR in ACS with prasugrel loading are also unknown.
Purpose
To assess the effects of post-procedural HPR with prasugrel loading on clinical outcomes in ACS during hospitalization, and to define the appropriate cut-off values and identify factors contributing to HPR.
Methods
A single-center, retrospective observational study that enrolled 154 patients who underwent emergent PCI for ACS with prasugrel loading was performed.
The P2Y12 reaction unit (PRU) value was measured immediately after PCI using the VerifyNowR system.
The primary end-point was major adverse cardiac events (MACE, defined as the composite of death, myocardial infarction, stroke, heart failure, ventricular arrhythmia needing defibrillation).
Results
The mean patient age (standard deviation) was 70.
7 (±12.
5) years, 76.
6% were men, and the average time from the prasugrel intake to PRU calculation was 103.
2 (±48.
5) min.
During the mean hospital stay of 15.
6 (±8.
5) days, 24 in-hospital MACE (15.
5%) and 8 deaths (5.
2%) occurred.
Thrombosis events, including myocardial infarction recurrence, did not occur (only one case of spontaneous coronary artery dissection was considered as myocardial infarction recurrence).
PRU was significantly higher in the MACE group than that in Non-MACE group (287±55 and 232±64, respectively, p<0.
001).
The ROC curve analysis of PRU for discriminating the significant in-hospital MACE showed the cut-off value of 293 (sensitivity: 62.
5%, specificity: 83.
1% [AUC=0.
756, p<0.
0001]).
A total of 37 patients (24%) were thus categorized as HPR (PRU>293) immediately after the emergent PCI.
Kaplan-Meier curve showing MACE events occurred in the HPR group than that in the non-HPR group (40.
5% vs 7.
6%, p<0.
001).
Multiple cox analysis demonstrated that HPR was independent predictors of MACE in patients with ACS who underwent PCI (OR 11.
01, 95% CI 2.
39–20.
2, p<0.
0001).
Multiple logistic regression model showed old age, female sex, low systolic blood pressure, short prasugrel intake to measure time, and large acute gain were independent predictors of HPR.
Conclusion
PRU was significantly higher in the MACE group, with an appropriate cut-off value of HPR of 293 in this study.
HPR was an independent predictor of MACE during hospitalization; however, thrombosis events were not significant.
HPR predictors were old age, female sex, low systolic blood pressure, short prasugrel intake to measure time, and large acute gain.
This study shows the post-procedural HPR with prasugrel loading in patients with ACS can be a useful predictive marker of adverse events during hospitalization.
Funding Acknowledgement
Type of funding source: None.
Related Results
P4634Acute-phase high platelet reactivity with prasugrel loading is correlated with clinical outcomes during hospitalization in acute coronary syndrome
P4634Acute-phase high platelet reactivity with prasugrel loading is correlated with clinical outcomes during hospitalization in acute coronary syndrome
Abstract
Background/Introduction
Although high platelet reactivity (HPR) seems to be associated with adverse cardiovascular even...
ASSOCIATION OF THE SERUM LEVELS OF C-REACTIVE PROTEIN WITH ITS GENE POLYMORPHISMS AND ACUTE CORONARY SYNDROME
ASSOCIATION OF THE SERUM LEVELS OF C-REACTIVE PROTEIN WITH ITS GENE POLYMORPHISMS AND ACUTE CORONARY SYNDROME
Objectives
To investigate the association of the serum levels of CRP with its gene polymorphisms and the risk of ACS in Chinese Han population in Sunan region.
...
E-071 Organization of a Neurointerventional Fellowship Curriculum
E-071 Organization of a Neurointerventional Fellowship Curriculum
Introduction
The field of Neurointervention has attracted some of the very best physicians across the world. Given the interdisciplinary nature of this specialty,...
PATHOPHYSIOLOGY OF THROMBOCYTOPENIA AND RESULTANT CLINICAL INDICATIONS FOR PLATELET TRANSFUSION
PATHOPHYSIOLOGY OF THROMBOCYTOPENIA AND RESULTANT CLINICAL INDICATIONS FOR PLATELET TRANSFUSION
Careful evaluation of platelet survival data in normal individuals and patients with thrombocytopeniasecondary to marrow aplasia has demonstrated that platelets are lost from circu...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
GW24-e2375 Onset of antiplatelet effect of prasugrel and ticagrelor is delayed in patients with acute coronary syndromes
GW24-e2375 Onset of antiplatelet effect of prasugrel and ticagrelor is delayed in patients with acute coronary syndromes
Objectives
A more rapid onset of antiplatelet effect following loading with prasugrel and ticagrelor compared to clopidogrel was demonstrated for healthy subjects...
Comparative efficacy and safety of ticagrelor vs. prasugrel in patients undergoing PCI for NSTE-ACS. Results of the prospective ALKK-Registry
Comparative efficacy and safety of ticagrelor vs. prasugrel in patients undergoing PCI for NSTE-ACS. Results of the prospective ALKK-Registry
Abstract
Background
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has become standard of care for patients with N...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...

